- Home
- IDT vs ZYME Comparison
IDT vs ZYME Comparison
Compare IDT & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDT
- ZYME
- Stock Information
- Founded
- IDT 1990
- ZYME 2003
- Country
- IDT United States
- ZYME United States
- Employees
- IDT N/A
- ZYME N/A
- Industry
- IDT Telecommunications Equipment
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- IDT Telecommunications
- ZYME Health Care
- Exchange
- IDT Nasdaq
- ZYME Nasdaq
- Market Cap
- IDT 1.3B
- ZYME 983.6M
- IPO Year
- IDT 1996
- ZYME 2017
- Fundamental
- Price
- IDT $47.28
- ZYME $12.55
- Analyst Decision
- IDT
- ZYME Buy
- Analyst Count
- IDT 0
- ZYME 6
- Target Price
- IDT N/A
- ZYME $19.50
- AVG Volume (30 Days)
- IDT 98.6K
- ZYME 607.8K
- Earning Date
- IDT 03-06-2025
- ZYME 03-05-2025
- Dividend Yield
- IDT 0.50%
- ZYME N/A
- EPS Growth
- IDT 117.27
- ZYME N/A
- EPS
- IDT 3.15
- ZYME N/A
- Revenue
- IDT $1,221,391,000.00
- ZYME $76,304,000.00
- Revenue This Year
- IDT N/A
- ZYME $19.85
- Revenue Next Year
- IDT N/A
- ZYME $100.06
- P/E Ratio
- IDT $15.11
- ZYME N/A
- Revenue Growth
- IDT 1.75
- ZYME 0.38
- 52 Week Low
- IDT $33.84
- ZYME $7.97
- 52 Week High
- IDT $58.77
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- IDT 44.87
- ZYME 44.21
- Support Level
- IDT $45.07
- ZYME $10.96
- Resistance Level
- IDT $52.47
- ZYME $13.18
- Average True Range (ATR)
- IDT 1.64
- ZYME 0.70
- MACD
- IDT -0.02
- ZYME -0.11
- Stochastic Oscillator
- IDT 29.86
- ZYME 46.36
About IDT IDT Corporation Class B
IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.